Bayer settles some NSF cases
Radiology ‘Wikipedia’ settles in on web
Bayer settles some NSF cases
Bayer has tentatively settled between 30 and 40 lawsuits brought by patients who developed nephrogenic systemic fibrosis after the administration of Magnevist, its MR contrast agent. Only Bayer has so far reached any such settlements, according to Peter Burg, an attorney with Burg Simpson Eldredge Hersh & Jardine in Englewood, CO, who told DI SCAN that not all of the tentative deals involve his clients. Bayer and several other makers of gadolinium-based contrast agents are facing hundreds of lawsuits alleging a link between the administration of the agents and NSF, a potentially fatal disease characterized by uncontrolled growth of connective tissue in the skin and internal organs. In September 2007, the FDA asked manufacturers of these agents -- Bayer (Magnevist), GE Healthcare (Omniscan), Mallinckrodt/Tyco Healthcare (OptiMark), and Bracco Diagnostics (ProHance and MultiHance) -- to add a black-box warning about NSF. The agency at the time also warned patients with impaired kidney function to avoid gadolinium-containing agents.
Radiology ‘Wikipedia' settles in on web
A specialist version of Wikipedia aimed at the radiology community is on the web. Radiopaedia.org is a free online radiology resource built and maintained by users, who find and correct errors. Currently in beta form, Radiopaedia.org is being framed as the means to support discussion of difficult or controversial topics. Images and other materials can be submitted and downloaded for use by others under Creative Commons 3.0 license.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
